Julie E Bauman1, Loren S Michel, Christine H Chung. 1. Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico Cancer Center, Albuquerque, New Mexico, USA.
Abstract
PURPOSE OF REVIEW: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. RECENT FINDINGS: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. SUMMARY: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.
PURPOSE OF REVIEW: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. RECENT FINDINGS: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. SUMMARY: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.
Authors: M Dang; J T Lysack; T Wu; T W Matthews; S P Chandarana; N T Brockton; P Bose; G Bansal; H Cheng; J R Mitchell; J C Dort Journal: AJNR Am J Neuroradiol Date: 2014-09-25 Impact factor: 3.825
Authors: C R Pickering; K Shah; S Ahmed; A Rao; M J Frederick; J Zhang; A K Unruh; J Wang; L E Ginsberg; A J Kumar; J N Myers; J D Hamilton Journal: AJNR Am J Neuroradiol Date: 2013-06-13 Impact factor: 3.825
Authors: Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-03-07 Impact factor: 2.503
Authors: Marcelo dos Santos; Ana Maria da Cunha Mercante; Iúri Drumond Louro; Antônio José Gonçalves; Marcos Brasilino de Carvalho; Eloiza Helena Tajara da Silva; Adriana Madeira Álvares da Silva Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: Felicity C Kalinowski; Keith M Giles; Patrick A Candy; Alishum Ali; Clarissa Ganda; Michael R Epis; Rebecca J Webster; Peter J Leedman Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240
Authors: Paulo Bentes de Carvalho-Neto; Marcelo dos Santos; Marcos Brasilino de Carvalho; Ana Maria da Cunha Mercante; Viviane Priscila Pina dos Santos; Patrícia Severino; Eloiza Helena Tajara; Iuri Drumond Louro; Adriana Madeira Álvares da Silva-Conforti Journal: PLoS One Date: 2013-07-19 Impact factor: 3.240